[
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "No HLA-B*15:02 Result"
        },
        "classification": "Optional",
        "comments": null,
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.",
        "drugrecommendation_short": "If alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351299",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "No *15:02 Result"
        },
        "phenotypes": {},
        "population": "CBZ-no alternatives",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have very limited evidence, if any, linking SJS/TEN, DRESS, and/or MPE with the HLA-A*31:01 allele, and thus no recommendation can be made with respect to choosing another aromatic anticonvulsant as an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve and alternative agents are available, do not use carbamazepine.",
        "drugrecommendation_short": "If patient is carbamazepine-na\u00efve and alternative agents are available, do not use carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351284",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "No HLA-A*31:01 Result",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351285",
        "implications": {
            "HLA-A": "n/a",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "No *31:01 Result",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "drugrecommendation_short": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351286",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "drugrecommendation_short": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351287",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "No HLA-A*31:01 Result",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "drugrecommendation_short": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351288",
        "implications": {
            "HLA-A": "n/a",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "No *31:01 Result",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "No HLA-B*15:02 Result"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351289",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "No *15:02 Result"
        },
        "phenotypes": {},
        "population": "CBZ naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "No HLA-B*15:02 Result"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have very limited evidence, if any, linking SJS/TEN, DRESS, and/or MPE with the HLA-A*31:01 allele, and thus no recommendation can be made with respect to choosing another aromatic anticonvulsant as an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve and alternative agents are available, do not use carbamazepine.",
        "drugrecommendation_short": "If patient is carbamazepine-na\u00efve and alternative agents are available, do not use carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351290",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "No *15:02 Result"
        },
        "phenotypes": {},
        "population": "CBZ naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351291",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351292",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ-no alternatives",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Optional",
        "comments": null,
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.",
        "drugrecommendation_short": "If alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351293",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ-no alternatives",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "No HLA-A*31:01 Result",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351294",
        "implications": {
            "HLA-A": "n/a",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "No *31:01 Result",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ-no alternatives",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "drugrecommendation_short": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351295",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ-no alternatives",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "drugrecommendation_short": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351296",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ-no alternatives",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "No HLA-A*31:01 Result",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "drugrecommendation_short": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351297",
        "implications": {
            "HLA-A": "n/a",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "No *31:01 Result",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ-no alternatives",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "No HLA-B*15:02 Result"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351298",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "No *15:02 Result"
        },
        "phenotypes": {},
        "population": "CBZ-no alternatives",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351300",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ use >3mos ",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",
        "drugrecommendation_short": "If the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351301",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ use >3mos ",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "No HLA-A*31:01 Result",
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351302",
        "implications": {
            "HLA-A": "n/a",
            "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "No *31:01 Result",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "CBZ use >3mos ",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "drugrecommendation_short": "If the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351303",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ use >3mos ",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "drugrecommendation_short": "If the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351304",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ use >3mos ",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "No HLA-A*31:01 Result",
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "drugrecommendation_short": "If the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351305",
        "implications": {
            "HLA-A": "n/a",
            "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-A": "No *31:01 Result",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "CBZ use >3mos ",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 negative",
            "HLA-B": "No HLA-B*15:02 Result"
        },
        "classification": "Strong",
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use carbamazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351306",
        "implications": {
            "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "HLA-A": "*31:01 negative",
            "HLA-B": "No *15:02 Result"
        },
        "phenotypes": {},
        "population": "CBZ use >3mos ",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-A": "HLA-A*31:01 positive",
            "HLA-B": "No HLA-B*15:02 Result"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
        "drug": {
            "name": "carbamazepine"
        },
        "drugid": "RxNorm:2002",
        "drugrecommendation": "The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",
        "drugrecommendation_short": "If the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1351307",
        "implications": {
            "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "HLA-A": "*31:01 positive",
            "HLA-B": "No *15:02 Result"
        },
        "phenotypes": {},
        "population": "CBZ use >3mos ",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "oxcarbazepine"
        },
        "drugid": "RxNorm:32624",
        "drugrecommendation": "Use oxcarbazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use oxcarbazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1352240",
        "implications": {
            "HLA-B": "Normal risk of oxcarbazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "OXC naive",
        "version": "1"
    },
    {
        "activityscore": {},
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
        "drug": {
            "name": "oxcarbazepine"
        },
        "drugid": "RxNorm:32624",
        "drugrecommendation": "If patient is oxcarbazepine-na\u00efve, do not use oxcarbazepine.",
        "drugrecommendation_short": "If patient is oxcarbazepine-na\u00efve, do not use oxcarbazepine.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1352241",
        "implications": {
            "HLA-B": "Greater risk of oxcarbazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "OXC naive",
        "version": "1"
    },
    {
        "activityscore": {
            "HLA-B": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "oxcarbazepine"
        },
        "drugid": "RxNorm:32624",
        "drugrecommendation": "Use oxcarbazepine per standard dosing guidelines.",
        "drugrecommendation_short": "Use oxcarbazepine per standard dosing guidelines.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1352242",
        "implications": {
            "HLA-B": "Normal risk of oxcarbazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {},
        "population": "OXC use >3 mos",
        "version": "1"
    },
    {
        "activityscore": {
            "HLA-B": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
        "drug": {
            "name": "oxcarbazepine"
        },
        "drugid": "RxNorm:32624",
        "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.",
        "drugrecommendation_short": "If the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.",
        "guideline": {
            "name": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine"
        },
        "guidelineid": "100423",
        "id": "1352243",
        "implications": {
            "HLA-B": "Greater risk of oxcarbazepine-induced SJS/TEN"
        },
        "lookupkey": {
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {},
        "population": "OXC use >3 mos",
        "version": "1"
    }
]